Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2014

01-04-2014 | Review Article

A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy

Authors: Efstratios Stratikos, Angeliki Chroni

Published in: Clinical and Experimental Nephrology | Issue 2/2014

Login to get access

Abstract

Single amino acid mutations in apolipoprotein E (apoE) have been associated with the development of the rare kidney disease lipoprotein glomerulopathy (LPG). Although the genetic linkage to disease development is well established, the mechanism of pathogenesis is largely unknown, limiting therapeutic insight. Here, we summarize current knowledge in the field and focus on the possible effects of LPG-associated mutations on the structure of apoE. Recent findings have suggested that mutation-induced folding perturbations in apoE lead to structural destabilization and aggregation, effects that may underlie lipoprotein thrombi accumulation in the glomerulus, a hallmark of LPG. The recognition that structural destabilization may underlie the association between apoE mutations and LPG can be key for development of new innovative treatments for this rare disease.
Literature
1.
2.
go back to reference Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47(2):199–211.PubMedCrossRef Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47(2):199–211.PubMedCrossRef
3.
go back to reference Rovin BH, Roncone D, McKinley A, Nadasdy T, Korbet SM, Schwartz MM. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med. 2007;357(24):2522–4.PubMedCrossRef Rovin BH, Roncone D, McKinley A, Nadasdy T, Korbet SM, Schwartz MM. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med. 2007;357(24):2522–4.PubMedCrossRef
4.
go back to reference Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JAL, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006;47(3):539–48.PubMedCrossRef Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JAL, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006;47(3):539–48.PubMedCrossRef
5.
go back to reference Bomback AS, Song H, D’Agati VD, Cohen SD, Neal A, Appel GB, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European–American with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2010;25(10):3442–6.PubMedCrossRef Bomback AS, Song H, D’Agati VD, Cohen SD, Neal A, Appel GB, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European–American with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2010;25(10):3442–6.PubMedCrossRef
6.
go back to reference Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Rep. 2009;3:9311.PubMedCentralPubMedCrossRef Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Rep. 2009;3:9311.PubMedCentralPubMedCrossRef
7.
go back to reference Mourad G, Cristol JP, TurcBaron C, Djamali A. Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Transplant Proc. 1997;29(5):2376.PubMedCrossRef Mourad G, Cristol JP, TurcBaron C, Djamali A. Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Transplant Proc. 1997;29(5):2376.PubMedCrossRef
8.
go back to reference Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med. 2002;12(2):67–70.PubMedCrossRef Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med. 2002;12(2):67–70.PubMedCrossRef
9.
go back to reference Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem. 2000;275(40):31269–73.PubMedCrossRef Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem. 2000;275(40):31269–73.PubMedCrossRef
10.
go back to reference Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30.PubMedCrossRef Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30.PubMedCrossRef
11.
go back to reference Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res. 1982;23(6):911–4.PubMed Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res. 1982;23(6):911–4.PubMed
12.
go back to reference Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res. 2009;50 Suppl:S183–8.PubMed Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res. 2009;50 Suppl:S183–8.PubMed
13.
go back to reference Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT. Human apolipoprotein E3 in aqueous solution II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988;263(13):6249–58.PubMed Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT. Human apolipoprotein E3 in aqueous solution II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988;263(13):6249–58.PubMed
14.
go back to reference Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. Human apolipoprotein E3 in aqueous solution I. Evidence for two structural domains. J Biol Chem. 1988;263(13):6240–8.PubMed Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. Human apolipoprotein E3 in aqueous solution I. Evidence for two structural domains. J Biol Chem. 1988;263(13):6240–8.PubMed
15.
go back to reference Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011;108(36):14813–8.PubMedCentralPubMedCrossRef Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011;108(36):14813–8.PubMedCentralPubMedCrossRef
16.
go back to reference Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry. 2008;47(35):9071–80.PubMedCentralPubMedCrossRef Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry. 2008;47(35):9071–80.PubMedCentralPubMedCrossRef
17.
go back to reference Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001.
18.
go back to reference Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. PLoS One. 2011;6(11):e27037.PubMedCentralPubMedCrossRef Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. PLoS One. 2011;6(11):e27037.PubMedCentralPubMedCrossRef
19.
go back to reference Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, et al. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Biochemistry. 2010;49(51):10881–9.PubMedCentralPubMedCrossRef Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, et al. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Biochemistry. 2010;49(51):10881–9.PubMedCentralPubMedCrossRef
20.
go back to reference Johnson LA, Arbones-Mainar JM, Fox RG, Pendse AA, Altenburg MK, Kim HS, et al. Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes. 2011;60(9):2285–94.PubMedCentralPubMedCrossRef Johnson LA, Arbones-Mainar JM, Fox RG, Pendse AA, Altenburg MK, Kim HS, et al. Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes. 2011;60(9):2285–94.PubMedCentralPubMedCrossRef
21.
go back to reference Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.PubMedCrossRef Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.PubMedCrossRef
22.
go back to reference Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem. 1996;271(32):19053–7.PubMedCrossRef Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem. 1996;271(32):19053–7.PubMedCrossRef
23.
go back to reference Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol. 1996;3(8):718–22.PubMedCrossRef Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol. 1996;3(8):718–22.PubMedCrossRef
24.
go back to reference Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 2001;12(3):524–30.PubMed Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 2001;12(3):524–30.PubMed
25.
go back to reference Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56(2):421–7.PubMedCrossRef Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56(2):421–7.PubMedCrossRef
26.
go back to reference Murano T, Matsumura R, Misawa Y, Ozaki H, Miyashita Y, Yoshida S, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg → Cys) from a patient with lipoprotein glomerulopathy. Metabolism. 2002;51(2):201–5.PubMedCrossRef Murano T, Matsumura R, Misawa Y, Ozaki H, Miyashita Y, Yoshida S, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg → Cys) from a patient with lipoprotein glomerulopathy. Metabolism. 2002;51(2):201–5.PubMedCrossRef
27.
go back to reference Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.CrossRef Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.CrossRef
28.
go back to reference Georgiadou D, Stamatakis K, Efthimiadou EK, Kordas G, Gantz D, Chroni A, et al. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. J Lipid Res. 2013;54(1):164–76.PubMedCentralPubMedCrossRef Georgiadou D, Stamatakis K, Efthimiadou EK, Kordas G, Gantz D, Chroni A, et al. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. J Lipid Res. 2013;54(1):164–76.PubMedCentralPubMedCrossRef
29.
go back to reference Mahley RW, Huang Y. Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem. 2012;55(21):8997–9008.PubMedCrossRef Mahley RW, Huang Y. Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem. 2012;55(21):8997–9008.PubMedCrossRef
30.
go back to reference Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci USA. 2006;103(15):5644–51.PubMedCentralPubMedCrossRef Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci USA. 2006;103(15):5644–51.PubMedCentralPubMedCrossRef
31.
go back to reference Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem. 2012;287(8):5253–66.PubMedCentralPubMedCrossRef Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem. 2012;287(8):5253–66.PubMedCentralPubMedCrossRef
32.
go back to reference Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem. 2011;286(19):17217–26.PubMedCentralPubMedCrossRef Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem. 2011;286(19):17217–26.PubMedCentralPubMedCrossRef
33.
go back to reference Hagiwara M, Yamagata K, Matsunaga T, Arakawa Y, Usui J, Shimizu Y, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(1):381–4.PubMedCrossRef Hagiwara M, Yamagata K, Matsunaga T, Arakawa Y, Usui J, Shimizu Y, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(1):381–4.PubMedCrossRef
34.
go back to reference Konishi K, Saruta T, Kuramochi S, Oikawa S, Saito T, Han H, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83(3):214–8.PubMedCrossRef Konishi K, Saruta T, Kuramochi S, Oikawa S, Saito T, Han H, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83(3):214–8.PubMedCrossRef
35.
go back to reference Ogawa T, Maruyama K, Hattori H, Arai H, Kondoh I, Egashira T, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14(2):149–51.PubMedCrossRef Ogawa T, Maruyama K, Hattori H, Arai H, Kondoh I, Egashira T, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14(2):149–51.PubMedCrossRef
36.
go back to reference Maruyama K, Arai H, Ogawa T, Tomizawa S, Morikawa A. Lipoprotein glomerulopathy: a pediatric case report. Pediatr Nephrol. 1997;11(2):213–4.PubMedCrossRef Maruyama K, Arai H, Ogawa T, Tomizawa S, Morikawa A. Lipoprotein glomerulopathy: a pediatric case report. Pediatr Nephrol. 1997;11(2):213–4.PubMedCrossRef
37.
go back to reference Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, et al. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8(5):820–3.PubMed Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, et al. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8(5):820–3.PubMed
38.
go back to reference Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol. 2008;28(2):347–53.PubMedCentralPubMedCrossRef Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol. 2008;28(2):347–53.PubMedCentralPubMedCrossRef
39.
go back to reference Kinomura M, Sugiyama H, Saito T, Matsunaga A, Sada KE, Kanzaki M, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(2):751–6.PubMedCrossRef Kinomura M, Sugiyama H, Saito T, Matsunaga A, Sada KE, Kanzaki M, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(2):751–6.PubMedCrossRef
40.
go back to reference Mitani A, Ishigami M, Watase K, Minakata T, Yamamura T. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011;18(6):531–5.PubMedCrossRef Mitani A, Ishigami M, Watase K, Minakata T, Yamamura T. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011;18(6):531–5.PubMedCrossRef
41.
go back to reference Tokura T, Itano S, Kobayashi S, Kuwabara A, Fujimoto S, Horike H, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011;18(6):536–41.PubMedCrossRef Tokura T, Itano S, Kobayashi S, Kuwabara A, Fujimoto S, Horike H, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011;18(6):536–41.PubMedCrossRef
42.
go back to reference Ando M, Sasaki J, Hua H, Matsunaga A, Uchida K, Jou K, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int. 1999;56(4):1317–23.PubMedCrossRef Ando M, Sasaki J, Hua H, Matsunaga A, Uchida K, Jou K, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int. 1999;56(4):1317–23.PubMedCrossRef
43.
go back to reference Cheung CY, Chan AO, Chan YH, Lee KC, Chan GP, Lau GT, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J. 2009;15(1):57–60.PubMed Cheung CY, Chan AO, Chan YH, Lee KC, Chan GP, Lau GT, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J. 2009;15(1):57–60.PubMed
Metadata
Title
A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy
Authors
Efstratios Stratikos
Angeliki Chroni
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0886-5

Other articles of this Issue 2/2014

Clinical and Experimental Nephrology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.